The Effect of miR-17-5p on Vascular Lesion and Expression of VLDLR in Atherosclerotic Mice

TAN Li-li, LIU Li-min, ZHANG Xiu-chun, PIAO Cheng-hao

Abstract

To investigate the effect of miR-17-5p on vascular lesion and expression of very low density lipoprotein receptor (VLDLR) in atherosclerotic (AS) mice. Methods ApoE-/-mice were fed with high fat diet for 15 weeks to establish atherosclerotic mice models, and these mice were injected with miR-17-5p inhibitor antagomiR-17-5p 20 mg/kg from week 13 to week 15 to interfere the expression of miR-17-5p. AS model group (injection of normal saline) and NC miRNA group (injection of negative control inhibitors) were set and C57BL/6 mice were fed with normal diet for 15 weeks as normal control group (NC group, injection of normal saline during week 13-15). HE staining was used to detect the pathological changes of arterial vessels in each group and the vascular morphological changes were measured as well, so as to investigate the therapeutic effect of interfering miR-17-5p on AS vascular lesions. According to the prediction of Targetscan target gene prediction database, VLDLR as the target gene of miR-17-5p, the distribution of VLDLR in vascular tissues of mice in each group was observed by immunofluorescence. The effect of miR-17-5p on the expression of VLDLR mRNA in the arterial tissues of each group was detected by real-time PCR, and the changes of VLDLR protein expression caused by miR-17-5p in the arterial tissues in each group was detected by Western blot. Results The results of HE staining showed that compared with the NC group, the AS model group had obvious plaques in vascular endothelium, smooth muscle cell disorder and intimal hyperplasia, while the antagomiR-17-5p treated mice had significantly less lesions compared with the NC miRNA group. The intimal area of mice in the AS model group was bigger compared with NC group, but decreased after the inhibition of miR-17-5p. There was no statistically significant difference in the area of the media in each group. Vascular lumen area was smaller and intima/media ratio (I/M) values were lower in the AS model group and the NC miRNA group compared with the NC group, while the antagomiR-17-5p group alleviated this effect (P<0.05). Immunofluorescence showed that the expression of VLDLR in the AS model group was decreased, and that in the antagomiR-17-p group was higher than that in the NC miRNA group. The expression of VLDLR gene in the AS model group was lower than that in the NC group (P<0.01), while the VLDLR gene expression was higher in the antagomiR17-p group than that in the NC miRNA group (P<0.05). The results of VLDLR expression detected by Western blot were similar. Conclusion miR-17-5p inhibitors may effectively alleviate the pathological changes of arterial vessels in AS mice by up-regulating the expression of VLDLR in arterial tissues, and may become a new therapeutic target for AS disease.

 

Keywords: miR-17-5p, Atherosclerotic, Very low density lipoprotein receptor 

 

Full Text:

PDF


References


WILLIAMS KJ, WU X. Imbalanced insulin action in chronic over nutrition; clinical harm, molecular mechanisms, and a way forward. Atherosclerosis, 2016, 247; 225-282 [2017-03- 22].

LEONG XF, JAARIN K. Animal models in cardiovascular research: hypertension and atherosclerosis. Biomed Res Int, 2015,15:528-757[2018-04-l 1 ]. https://www. hindawi. com/ journals/bmri/2015/528757/.doi: 10.1155/2015/528757.

WANG L, TANG W, YAN S, et al. Efficient delivery of miR-122 to regulate cholesterol metabolism using a non- covalent peptide-based strategy. Mol Med Rep, 2013, 8(5) : 1472-1478.

LEE J, LIM S, SONG BW. et al. MicroRNA-29b inhibits migration and proliferation of vascular smooth muscle cells in neointimal formation. J Cell Bioch,2014,116(4):598-608.

CHENJ, XU L, HU Q, et al. MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int J Cardiol, 2015, 197: 123-124. [ 2017-03-21 ]. https ://www. sciencedirect. com/science/ article/pii/SO 167527315013388? via% 3Dihub . doi:10.1016/j. ijcard. 2015.06.037.

VAN WYNSBERGHE PM. CHAN SP, SLACK FJ, et al. Analysis of microRNA expression and function. Methods Cell Biol,2011,106(4) :219-252.

RAYNER KJ. SUAREZ Y, DAVALOS A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science,2010,328(5985): 1570-1573.

ASGERIRSOTTIR SA, SOLINGEN C, KURNIATI NF. et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am J Ren Physiol.2012.302( 12): 1630-1639.

LI Z, HASSAN MQ, JAFFERJI M, et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem,2009,284(23); 15676- 15684.

BENTWICH I. AVNIEI- A, KAROV Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet,2005,37(7) :766-770.

DOEBELE C, BONAUER A, FISCHER A, et al. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood, 2010, 115 (23) :4944-4950.

PARK SW, MOONYA, HORTON JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem,2004,279(48);50630-50638.

MACDOUGALL ED, KRAMER F, POLINSKY P. et al. Aggressive very low-density lipoprotein (VLDL) and LI)L lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. Am J Pathol,2006 , 168 ( 6 ): 2064-2073.


Refbacks

  • There are currently no refbacks.